Search
XC221
go.drugbank.com/drugs/DB16503InvestigationalXC221 was investigated in clinical trials to treat patients with respiratory infections, including influenza, COVID-19, and other acute viral upper respiratory infections.
CAR BCMA-CS1
go.drugbank.com/drugs/DB17313ExperimentalCAR BCMA-CS1 is a lentiviral transfected chimeric antigen receptor (CAR) T-cell therapy modified to target B-cell maturation antigen and CS1.
Divesiran
go.drugbank.com/drugs/DB18646InvestigationalDivesiran is a synthetic double-stranded siRNA oligonucleotide directed against TMPRSS6 mRNA and covalently linked to a ligand containing 3 N-acetylgalactosamine residues.
MBP134
go.drugbank.com/drugs/DB18686ExperimentalMBP134 is a pan-ebolavirus cocktail comprising two broadly neutralizing human antibodies. It is under investigation for the treatment of Sudan ebolavirus (SUDV).
Synonyms: Two immunoglobulin subclass 1 (IgG1) human monoclonal antibodies that target the Sudan ebolavirus glycoproteinCamoteskimab
go.drugbank.com/drugs/DB18876InvestigationalCamoteskimab is under investigation in clinical trial NCT06436183 (A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis).
Semzuvolimab
go.drugbank.com/drugs/DB18920InvestigationalSemzuvolimab is under investigation in clinical trial NCT03149211 (To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults).
Azafenidin
go.drugbank.com/drugs/DB19031InvestigationalAzafenidin is under investigation in clinical trial NCT01726582 (Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")).
Synonyms: 2-(2,4-dichloro-5-(2-propynyloxy)phenyl)-5,6,7,8-tetrahydro-1,2,4-triazolo(4,3-a)pyridin-3(2h)-one, 2-(2,4-dichloro-5-prop-2-ynyloxyphenyl)-5,6,7,8-tetrahydro-1,2,4-triazolo(4,3-a)pyridin-3(2h)-one(3-Carboxy-2-(R)-Hydroxy-Propyl)-Trimethyl-Ammonium
go.drugbank.com/drugs/DB02648ExperimentalIt is used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias. [PubChem]
TG-100801
go.drugbank.com/drugs/DB05075InvestigationalIt is administered noninvasively as an eye drop and is designed to suppress VEGF mediated leakage and additional kinase targets associated with inflammation, edema, and angiogenesis which are the pathological
Elafin
go.drugbank.com/drugs/DB05161InvestigationalElafin’s ability to block the activity of destructive enzymes that are involved in inflammatory reactions makes it a highly promising active compound for the treatment of inflammatory lung diseases or